Quick Answer
Amphastar Pharmaceuticals, Inc. reported Total Revenue of $719.89 million for the year ending 2025.
- Amphastar Pharmaceuticals, Inc. showed a decrease of -1.7% in Total Revenue from 2024 to 2025.
- This data is from Amphastar Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $56.67 million | Q2 2017: $65.19 million | Q3 2017: $57.92 million | Q4 2017: $60.40 million | Q1 2018: $58.39 million | Q2 2018: $71.04 million | Q3 2018: $75.54 million | Q4 2018: $89.69 million | Q1 2019: $79.79 million | Q2 2019: $79.05 million | Q3 2019: $80.14 million | Q4 2019: $83.38 million | Q1 2020: $84.69 million | Q2 2020: $85.81 million | Q3 2020: $83.43 million | Q1 2021: $103.02 million | Q2 2021: $101.66 million | Q3 2021: $112.20 million | Q1 2022: $120.37 million | Q2 2022: $123.47 million | Q3 2022: $120.13 million | Q1 2023: $140.02 million | Q2 2023: $145.71 million | Q3 2023: $180.56 million | Q1 2024: $171.84 million | Q2 2024: $182.39 million | Q3 2024: $191.21 million | Q1 2025: $170.53 million | Q2 2025: $174.41 million | Q3 2025: $191.84 million.
- Over the full 10 years of available data (2016 to 2025), Amphastar Pharmaceuticals, Inc.'s Total Revenue has grown by 182.1%.
- Historical annual values: Fiscal year 2025: $719.89 million | Fiscal year 2024: $731.97 million | Fiscal year 2023: $644.40 million | Fiscal year 2022: $498.99 million | Fiscal year 2021: $437.77 million | Fiscal year 2020: $349.85 million | Fiscal year 2019: $322.36 million | Fiscal year 2018: $294.67 million | Fiscal year 2017: $240.18 million | Fiscal year 2016: $255.17 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: